[en] Several reports indicated that nuclear factor kappaB (NF-kappaB) activation by cytokines, cytotoxic drugs, or ionizing radiation protects cells against apoptosis. Therefore, we investigated the consequence of NF-kappaB inhibition on the efficiency of antineoplastic agents. HPB, HCT116, MCF7, and OVCAR-3 cells stably expressing a dominant negative IkappaBalpha inhibitor showed a decreased NF-kappaB activation following treatment with tumor necrosis factor a and various chemotherapeutic agents. However, there was no difference in survival between parental cells and cells expressing mutated IkappaBalpha. These studies suggest that, at least in these cell lines, stable NF-kappaB inhibition did not modify the response to cytotoxic drugs.
Siebenlist, U., Franzoso, G., and Brown, K. Structure, regulation, and function of NF-κB. Annu. Rev. Cell. Biol., 10: 405-455, 1994.
Perera, P-Y., Qureshi, N., and Vogel, S. N. Paclitaxel (Taxol)-induced NF-κB translocation in murine macrophages. Infect. Immun., 64: 878-884, 1996.
Piret, B., and Piette, J. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells. Nucleic Acids Res., 24: 4242-4248, 1996.
Das, K. C., and White, C. W. Activation of NF-κB by anlineoplastic agents. J. Biol. Chem., 272: 14914-14920, 1997.
Hellin, A-C., Calmant, P., Gielen, J., Bours, V., and Merville, M-P. Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene, 16: 1187-1195, 1997.
Yao, K-S., and O'Dwyer, P. J. Involvement of NF-κB in the induction of NAD(P)H: quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. Biochem. Pharmacol., 3: 275-282, 1995.
Brach, M. A., Hass, R., Sherman, M. L., Gunji. H., Weichselbaum, R., and Kufe, D. Ionizing radiation induces expression and binding activity of the nuclear factor κB. J. Clin. Invest., 88: 691-695, 1991.
Beg, A. A., and Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science (Washington DC), 274: 782-784, 1996.
Liu, Z., Hsu, H., Goeddel, D. V., and Karin, M Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell, 87: 565-576, 1996.
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Washington DC), 274: 787-789, 1996.
Wang, C-Y., Mayo, M. W.. and Baldwin, A. S. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. and Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature (Lond.), 376: 167-170, 1995.
Bertrand, F., Atfi, A., Cadoret, A., L'Allemain, G., Robin, H., Lascols, O., Capeau, J., and Cherqui, G. A role for nuclear factor κB in the antiapoptotic function of insulin. J. Biol. Chem., 275; 2931-2938, 1998.
Bargou, R. C., Emmerich, F., Krappmann, D., Bomert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dörken, B. Constitutive Nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest., 100: 2961-2969, 1997.
Limuro, Y., Nishiura, T., Hellerbrand, C., Behrns, K. E., Schoonhoven, R., Grisham, J. W., and Brenner, D. A. NFκB prevents apoptosis and liver dysfunction during liver regeneration. J. Clin. Invest., 101: 802-811, 1998.
Mayo, M. W., Wang, C-Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. C., Der, C. J., and Baldwin, A. S. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Washington DC), 278: 1812-1815, 1997.
Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., Fitzgerald, M. J., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J., 15: 4682-4690, 1996.
Sovak, M. A., Bellas, R. E., Kim, D. W., Zanievski, G. J., Rogers, A. E., and Traish, A. M. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 100: 2952-2960, 1997.
Cai, Z., Körner, M., Tarantino, N., and Chouaib, S. IκBα overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor-α-induced apoptosis. J. Biol. Chem., 272: 96-101, 1997.
Li, Y., Zhang, W., Mantell, L. L., Kazzaz, J. A., Fein, A. M., and Horowitz, S. Nuclear factor-κB is activated by hyperoxia but does not protect from cell death. J. Biol. Chem., 272: 20646-20649, 1997.
Whiteside, S. T., Ernst, M. K., LeBail, O., Laurent-Winter, C., Rice, N., and Israël, A. N- and C-terminal sequences control degradation of MAD/IκBα in response to inducers of NF-κB activity. Mol. Cell. Biol., 15: 5339-5345, 1995.
Ferreira, V., Tarantino, N., and Körner, M. Discrimination between RelA and RelB transcriptional regulation by a dominant negative mutant of IκBα. J. Biol. Chem., 273: 592-599, 1998.
Dejardin, E., Bonizzi, G., Bellahcène, A., Castronovo, V., Merville, M-P., and Bours, V. Highly-expressed p100/p52 (NFKB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene, 11: 1835-1841, 1995.
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science (Washington DC), 267: 1485-1488, 1995.
Sikic, B. I. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol., 34: 40-47, 1997.
Cai, Z., Stancou, R., Körner, M., and Chouaib, S. Impairment of Fas-antigen expression in Adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int. J. Cancer, 68: 535-546, 1996.